HC Wainwright Analysts Boost Earnings Estimates for Immunome

Immunome, Inc. (NASDAQ:IMNM) – Equities researchers at HC Wainwright boosted their FY2029 earnings per share estimates for Immunome in a research report issued on Wednesday, March 4th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn $0.69 per share for the year, up from their prior estimate of $0.63. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Immunome’s FY2030 earnings at $1.35 EPS.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 75.83%.

A number of other research analysts have also recently weighed in on the company. Lake Street Capital lifted their price objective on Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Craig Hallum upped their price objective on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday. Truist Financial assumed coverage on shares of Immunome in a research note on Monday, December 1st. They set a “buy” rating and a $36.00 target price for the company. Stephens cut their price target on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Immunome in a report on Thursday, January 15th. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.33.

Immunome Stock Performance

Shares of Immunome stock traded down $0.47 on Thursday, hitting $22.05. 260,603 shares of the company’s stock were exchanged, compared to its average volume of 1,550,569. The stock has a market capitalization of $2.43 billion, a PE ratio of -9.11 and a beta of 2.12. The company has a 50-day simple moving average of $22.78 and a 200-day simple moving average of $17.58. Immunome has a 1 year low of $5.15 and a 1 year high of $27.65.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. boosted its stake in shares of Immunome by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after acquiring an additional 5,003,824 shares in the last quarter. Vanguard Group Inc. grew its stake in Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after acquiring an additional 1,144,788 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. State Street Corp increased its stake in shares of Immunome by 37.9% in the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after acquiring an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Buying and Selling at Immunome

In other Immunome news, Director Isaac Barchas sold 383,200 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the sale, the director directly owned 2,031,181 shares in the company, valued at approximately $44,157,874.94. This represents a 15.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Clay B. Siegall bought 4,729 shares of the business’s stock in a transaction on Tuesday, December 30th. The shares were acquired at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the transaction, the chief executive officer directly owned 665,254 shares in the company, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 68,518 shares of company stock valued at $1,453,958 in the last three months. Company insiders own 7.69% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.